Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385217 | 0.87 | GPR119 (0.58) | GPR119 | |
| SCHEMBL2879360 | 0.86 | GPR119 (0.56) | GPR119GPR183 | |
| SCHEMBL4055470 | 0.85 | GPR119 (0.45) | GPR119GPR183PTGS2PTGS1 | |
| SCHEMBL3986213 | 0.85 | PTGS1 (0.43) | GPR119GPR183PTGS2PTGS1ACHE | |
| SCHEMBL3980457 | 0.83 | GPR119 (0.61) | GPR119GPR183 | |
| SCHEMBL4457000 | 0.80 | PTGS2 (0.44) | GPR119GPR183PTGS2PTGS1ACHE | |
| SCHEMBL1937388 | 0.76 | SLC6A9 (0.46) | GPR119PTGS2PTGS1 | |
| SCHEMBL4059388 | 0.75 | LMNA (0.44) | GPR119GPR183PTGS2PTGS1ACHE | |
| SCHEMBL4972827 | 0.75 | GPR119 (0.39) | GPR119 | |
| SCHEMBL384412 | 0.75 | GPR119 (0.50) | GPR119GPR183PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008025799-A1 | PYRIDAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| US-20080058339-A1 | New compounds | BIOVITRUM (SE) | 2008-03-06 | — | — | US | claimed |
| WO-2008025799-A1 | PYRIDAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| US-20080058339-A1 | New compounds | BIOVITRUM (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058339-A1 | New compounds | GPR119, GPR180, GPR139 | GPR119 1/4885GPR183 21/4885PTGS2 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.